369 related articles for article (PubMed ID: 31546908)
21. Well-defined reducible cationic nanogels based on functionalized low-molecular-weight PGMA for effective pDNA and siRNA delivery.
Li RQ; Wu W; Song HQ; Ren Y; Yang M; Li J; Xu FJ
Acta Biomater; 2016 Sep; 41():282-92. PubMed ID: 27267781
[TBL] [Abstract][Full Text] [Related]
22. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery.
Asai T; Tsuzuku T; Takahashi S; Okamoto A; Dewa T; Nango M; Hyodo K; Ishihara H; Kikuchi H; Oku N
Biochem Biophys Res Commun; 2014 Feb; 444(4):599-604. PubMed ID: 24486551
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
24. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
25. SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment.
Liu H; Li Y; Mozhi A; Zhang L; Liu Y; Xu X; Xing J; Liang X; Ma G; Yang J; Zhang X
Biomaterials; 2014 Aug; 35(24):6519-33. PubMed ID: 24797882
[TBL] [Abstract][Full Text] [Related]
26. siRNA delivery into tumor cells by lipid-based nanoparticles composed of hydroxyethylated cholesteryl triamine.
Hattori Y; Nakamura T; Ohno H; Fujii N; Maitani Y
Int J Pharm; 2013 Feb; 443(1-2):221-9. PubMed ID: 23279939
[TBL] [Abstract][Full Text] [Related]
27. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418
[TBL] [Abstract][Full Text] [Related]
28. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
Zhang J; Haas RM; Leone AM
Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
30. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
[TBL] [Abstract][Full Text] [Related]
31. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
32. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.
Wang X; Yu B; Ren W; Mo X; Zhou C; He H; Jia H; Wang L; Jacob ST; Lee RJ; Ghoshal K; Lee LJ
J Control Release; 2013 Dec; 172(3):690-8. PubMed ID: 24121065
[TBL] [Abstract][Full Text] [Related]
33. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
34. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.
Uemura Y; Naoi T; Kanai Y; Kobayashi K
Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101
[TBL] [Abstract][Full Text] [Related]
35. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
Kulkarni JA; Cullis PR; van der Meel R
Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
[TBL] [Abstract][Full Text] [Related]
36. Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.
Konca YU; Kirshenbaum K; Zuckermann RN
Int J Nanomedicine; 2014; 9():2271-85. PubMed ID: 24872690
[TBL] [Abstract][Full Text] [Related]
37. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver.
Zhang R; El-Mayta R; Murdoch TJ; Warzecha CC; Billingsley MM; Shepherd SJ; Gong N; Wang L; Wilson JM; Lee D; Mitchell MJ
Biomater Sci; 2021 Feb; 9(4):1449-1463. PubMed ID: 33404020
[TBL] [Abstract][Full Text] [Related]
38. Size-controlled lipid nanoparticle production using turbulent mixing to enhance oral DNA delivery.
He Z; Hu Y; Nie T; Tang H; Zhu J; Chen K; Liu L; Leong KW; Chen Y; Mao HQ
Acta Biomater; 2018 Nov; 81():195-207. PubMed ID: 30267888
[TBL] [Abstract][Full Text] [Related]
39. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
Sakurai Y; Hatakeyama H; Akita H; Harashima H
Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
[TBL] [Abstract][Full Text] [Related]
40. Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications.
Walsh C; Ou K; Belliveau NM; Leaver TJ; Wild AW; Huft J; Lin PJ; Chen S; Leung AK; Lee JB; Hansen CL; Taylor RJ; Ramsay EC; Cullis PR
Methods Mol Biol; 2014; 1141():109-20. PubMed ID: 24567134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
